Thesis, a New York City-based firm specializing in personalized cognitive performance products, has successfully completed an $8.4 million Series A funding round. The investors included Unilever Ventures, Redo Ventures, Alive VC, Break Trail, NBA star Kevin Love, and model Kate Bock. Prior to this round, the company had raised $5.1 million in a seed round from Unilever Ventures, MBX, Trust Ventures, and Redo Ventures, bringing the total funding to over $13.5 million.
The funds will be utilized to expand the product range and conduct clinical trials. Under the leadership of founder and CEO Dan Freed, Thesis develops potent nutrient blends tailored to individuals’ brain chemistry and desired cognitive states. The company offers products targeting specific outcomes, such as the Energy Formula for combating fatigue, the Clarity Formula for achieving flow states, and the Motivation Formula for reducing procrastination.
Thesis products are formulated with clinically tested active ingredients that possess the highest possible bioavailability and comply with FDA Current Good Manufacturing Processes (cGMP).
